Clinical Trial Update: Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pre-transplant purging and post-transplant MRD-guided maintenance therapy with elranatamab in high-risk multiple myeloma; recruitment i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy | Phase 2 | Status: RECRUITING